Its role Owner
Novo Nordisk is a global healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, it researches, develops, manufactures, and markets medicines for serious chronic diseases. The company is listed on Nasdaq Copenhagen, with American Depositary Receipts traded in the U.S.
Core areas include diabetes and obesity, as well as rare endocrine and blood disorders. Its portfolio spans human and analogue insulins, GLP-1–based therapies, and other peptide and protein biologics. Novo Nordisk operates extensive bioprocessing, active pharmaceutical ingredient production, formulation, and fill–finish facilities worldwide, and collaborates with academic and industry partners on emerging modalities such as cell therapy.
Also known as Novo and NVO.
chemXplore tracks 5 projects involving Novo Nordisk, of which 3 are active.
Besides these 3, the record holds 2 completed projects.
Closest to start-up first.
The 2 that are completed, on hold or cancelled are in the record. See all 5 in chemXplore →
The dates themselves, per project, are for subscribers.
Real‑world cohorts showed Wegovy 2.4 mg was associated with larger reductions in body weight, AST/ALT, and HbA1c versus resmetirom or no semaglutide in adults with MASH.
GLP‑1 volume growth drove sales and adjusted profit; reported profit hit by USD 1.4bn impairments; Wegovy and Ozempic pills expand launches while late‑stage pipeline advances.
GLP‑1 volume growth drove sales and margin expansion; reported profit hit by non‑cash impairments; Wegovy and Ozempic pill rollouts broadened; pipeline milestones support near‑term launches.
Reduces basal injections from seven to one per week; insulin icodec‑abae is U‑700, indicated for ages ≥10, supported by pediatric PK and ONWARDS clinical data.
Post hoc REDEFINE 1 analyses found once‑weekly cagrilintide/semaglutide produced large weight and waist‑circumference reductions across menopausal stages; main adverse events were gastrointestinal. FDA decision expected Q4 2026.
FDA review remains ongoing; extension caused by facility remediation, not clinical deficiencies. Novo still targets a US launch in H1 2027 and says 2026 outlook is unaffected.
MRI‑PDFF subanalysis (n=55) found mean liver fat fell from 8.8% to 3.1% at week 72; 88.5% with baseline liver fat >5% reached <5%.
Ro telehealth real-world data: mean 4.1% weight loss at three months; 40.7% reached ≥5% loss; obesity (BMI≥30) prevalence fell 21.6 percentage points; N=194.
